HER-2/neu amplification and overexpression in endometrial carcinoma

International Journal of Gynecological Pathology

Volumn 18, Issue 2, 1999, Pages 138-143

  Rolitsky, Chris D ^a   Theil, Karl S ^a   McGaughy, Violeta R ^a   Copeland, Larry J ^a   Niemann, Theodore H ^a,b  

^a OHIO STATE UNIVERSITY   (United States)

^b E 403 Doan Hall ^*  (United States)

Author keywords

Carcinoma; Endometrium; Fluorescence in situ hybridization; HER 2 neu; Uterus

Indexed keywords

ADULT; AGED; ARTICLE; DIAGNOSTIC VALUE; ENDOMETRIUM CARCINOMA; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; HUMAN; HUMAN TISSUE; ONCOGENE NEU; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 0032993938     PISSN: 02771691     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004347-199904000-00007     Document Type: Article

References (31)

1. Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics, 1998. CA Cancer J Clin 1998;48:6-29.
2. Zaino RJ. Taking another look at endometrial adenocarcinoma. Int J Gynecol Pathol 1996;15:187-190.
3. Zaino RJ, Kurman RJ, Diana KL, Morrow CP. Pathologic models to predict outcome for women with endometrial adenocarcinoma. The importance of the distinction between surgical stage and clinical stage: a gynecologic oncology group study. Cancer 1996;77: 1115-21.
4. Berchuck A, Boyd J, Molecular basis of endometrial cancer. Cancer 1995;76:2034-40.
5. Boyd J. Molecular biology in the clinicopathologic assessment of endometrial carcinoma subtypes. Gynecol Oncol 1996;61:163-5.
6. Schecter AL, Hung MC, Vaidyanathan L, et al. The neu gene: an erbB-homologous gene distinct from and unlinked to the gene encoding the EGF receptor. Science 1985;229:976-8.
7. Slamon DJ, Godolphin W, Jones LA, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989;264:707-12.
8. Muss HB, Thor AD, Berry DA, et al. C-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N Engl J Med 1994;330:1260-6.
9. Kohlberger P, Loesch A, Koelbl H, Breitenecker G, Kainz C, Gitsch G. Prognostic value of immunohistochemically detected HER-2/neu oncoprotein in endometrial cancer. Cancer Lett 1996; 98:151-5.
10. Scully RE, Bonfiglio TA, Kurman RJ, Silverberg SG, Wilkinson EJ. Histological Typing Of Female Genital Tract Tumors. 2nd ed. New York: Springer-Verlag, 1994:13-8.
11. FIGO stages: 1988 revisions. Gynecol Oncol 1989;35:125-7.
12. Visscher DW, Wallis T, Ritchie CA. Detection of chromosome aneuploidy in breast lesions with fluorescence in situ hybridization: comparison of whole nulcei to thin tissue sections and correlation with flow cytometric DNA analysis. Cytometry 1995;21: 95-100.
13. Hoefler H, Childers H, Montminy MR, Lechan RM, Goodman RH, Wolfe HJ. In situ hybridization methods for the detection of somatostatin mRNA in tissue sections using antisense RNA probes. Histochem J 1986;18:597-604.
14. Pauletti G, Godolphin W, Press MF, Slamon DJ. Detection and quantitation of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization. Oncogene 1996;13:63-7.
15. Lewis GD, Lofgren JA, McMurtrey AE, et al. Growth regulation of human breast and ovarian tumor cells by heregulin: evidence for the requirement of ErbB2 as a critical component mediating heregulin responsiveness. Cancer Res 1996;56:1457-65.
16. Brumm C, Riviere A, Wilckens C, Loning T. Immunohistochemical investigation and Northern blot analysis of c-erbB-2 expression in normal, premalignant, and malignant tissues of the corpus and cervix uteri. Virchows Arch A Parhol Anat Histopathol 1990; 417:477-84.
17. Borst MP, Baker VV, Dixon D, Hatch KD, Shingleton HM, Miller DM. Oncogene alterations in endometrial carcinoma. Gynecol Oncol 1990;38:364-6.
18. Berchuck A, Rodriguez G, Kinney RB, et al. Overexpression of HER-2/neu in endometrial cancer is associated with advanced stage disease. Am J Obstet Gynecol 1991;164:15-21.
19. Bigsby RM, Aixin LI, Bomalaski J, Stehman FB, Look KY, Sutton GP. Immunohistochemical study of HER-2/neu, epidermal growth factor receptor, and steroid receptor expression in normal and malignant endometrium. Obstet Gynecol 1992;79:95-100.
20. Hetzel DJ, Wilson TO, Keeney GL, Roche PC, Cha SS, Podratz KC. HER-2/neu expression: a major prognostic factor in endometrial cancer. Gynecol Oncol 1992;47:179-85.
21. Wang DP, Konishi I, Koshiyama M, et al. Expression of c-erb-B-2 protein and epidermal growth factor receptor in endometrial carcinomas. Cancer 1993;72:28-37.
22. Khalifa MA, Mannel RS, Haraway SD, Walker J, Min KW. Expression of EGFR, HER-2/neu, p53, and PCNA in endometrioid, serous papillary and clear cell endometrial adenocarcinomas. Gynecol Oncol 1994;53:84-92.
23. Reinartz JJ, George E, Lindgren BR, Niehans GA. Expression of p53, transforming growth factor alpha, epidermal growth factor receptor, and c-erb-2 in endometrial carcinoma and correlation with survival and known predictors of survival. Hum Pathol 1994;25:1075-83.
24. Lukes AS, Kohler MF, Pieper CF, et al. Multivariable analysis of DNA ploidy, p53, and Her-2/neu as prognostic factors in endometrial cancer. Cancer 1994;73:2380-85.
25. Nielsen AL, Nyholm HCJ. p53 protein and c-erb-B-2 protein (p185) expression in endometrial adenocarcinoma of endometrioid type. Am J Clin Pathol 1994;102:76-9.
26. Nazeer T, Ballouk F, Malfetano JH, Figge H, Ambros RA. Multivariate survival analysis of clinicopathologic features in surgical stage I endometrioid carcinoma including analysis of HER-2/neu expression. Am J Obstet Gynecol 1995;173:1829-34.
27. Saffari B, Jones LA, el-Naggar A, Felix JC, George J, Press MF. Amplification and overexpression of HER-2/neu (c-erbB-2) in endometrial cancers: correlation with overall survival. Cancer Res 1995;55:5693-98.
28. Esteller M, Garcia A, Martinez JM, Palones JMM, Cabero A, Reventes J. Detection of c-erb-B-2/neu and fibroblast growth factor-3/INT-2 but not epidermal growth factor receptor gene amplification in endometrial cancer by differential polymerase chain reaction. Cancer 1995;75:2139-46.
29. Riben MW, Malfetano JH, Nazeer T, Muraca PJ, Ambros RA, Ross JS. Identification of HER-2/neu oncogene amplification by fluorescence in situ hybridization in stage I endometrial carcinoma. Mod Pathol 1997;10:823-31.
30. Kay EW, Barry Walsh CJ, Cassidy M, Curran B, Leader M. C-erbB2 immunostaining: problems with interpretation. J Clin Pathol 1994;47:816-22.
31. Press MF, Hung G, Godolphin W, Slamon DJ. Sensitivity of HER-2/neu antibodies in archival tissue samples: potential source of error in immunohistochemical studies of oncogene expression. Cancer Res 1994;54:2771-7.